An interventional study of Lungpacer Diaphragm Pacing Therapy in Ventilator Induced Diaphragm Dysfunction, sponsored by Lungpacer Medical Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A single-arm, prospective, multicenter cohort study to assess the 30-day continued safety and effectiveness of the AeroPace System in patients on mechanical ventilation (MV) at least 96 hours and who have not weaned. This is a study collecting real-world data in a post-market setting.
Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject receives AeroPace therapy consisting of 60 stimulations, twice daily for a total of 120 stimulations/day, plus standard of care for weaning from mechanical ventilation including at least once daily spontaneous breathing trials.
Device: Lungpacer Diaphragm Pacing Therapy
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Also known as: Lungpacer DPTS, AeroPace System
Adverse Event Profile
All Serious Adverse Events from enrollment to study exit and device- and/or procedure-related Adverse Events until successful wean, withdrawal/death, transfer or day 30 (whichever comes first).
Time frame: 30 days
Successful Weaning
Proportion of subjects successfully weaned by Day 30
Time frame: 30 days
Days on mechanical ventilation from time of initial placement procedure through Day 30.
Time frame: 30 days
Incidence of reintubation/reinstatement of MV through Day 30
Time frame: 30 days
Incidence of device/procedure related SAEs as compared to RESCUE 3 Treatment group subjects
Time frame: 30 days
Mortality through Day 30
Time frame: 30 days
Incidence of tracheostomy from enrollment through Day 30
Time frame: 30 days
ICU/hospital days from initial placement procedure to Day 32
Time frame: 32 days
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Aug 2028, 22 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lungpacer Medical Inc.